Janssen submits sNDA to FDA for Invokana to reduce risk of MACE
Janssen Research and Development has submitted a supplemental New Drug Application (sNDA) to the US Food and Drug Administration (FDA) for Invokana (canagliflozin) to reduce the risk of major adverse cardiovascular events (MACE).
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news
More News: Canagliflozin | Cardiology | Cardiovascular | Food and Drug Administration (FDA) | Heart | Invokana | New Drug Applications